JPRN-jRCT1080224498已完成2 期
A clinical study of CL2020 in patients with epidermolysis bullosa
ife Science Institute, Inc.0 个研究点目标入组 5 人开始时间: 2018年12月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
CL2020 administration is a well-tolerated therapy and Muse cells are a potentially promising regenerative medicine for adults with severe EB.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Major inclusion criteria
- •Patients with epidermolysis bullosa who have any intractable ulcers
- •Patients aged 12 to 75 years
- •Female or male patients
排除标准
- •Major exclusion criteria
- •Patients with any existing or previous malignant tumor
- •Female patients who are or may be pregnant or who are breastfeeding
研究者
相似试验
已完成
不适用
Prospective Multicenter Registry of Patients With Skin Metastases From Breast Cancer Treated With ElectrochemotherapyBreast Cancer FemaleNCT06709937Fondazione Policlinico Universitario Agostino Gemelli IRCCS200
已完成
3 期
Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney TransplantsKidney Transplant RejectionNCT03363945Medeor Therapeutics, Inc.30
撤回
2 期
Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney TransplantsKidney Transplant RejectionNCT03606746Medeor Therapeutics, Inc.
已完成
1 期
Treatment CLI Nonrevascularizable Lower Limb With Cell TherapyNonrevascularizable Critical Ischemia of the Lower LimbsNCT01824069Instituto de Investigación Hospital Universitario La Paz10
招募中
1 期
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar DepressionTreatment-resistant Bipolar DepressionNCT03522545The University of Texas Health Science Center, Houston30